The critical challenge for cancer vaccine‐induced T‐cell immunity is the sustained activation
of antigen cross‐presentation in antigen‐presenting cells (APCs) with innate immune …

Insufficient tumor-infiltration of the cytotoxic T lymphocytes (CTLs) and immunosuppressive
tumor microenvironment (ITM) severely hinder T cell-based cancer immunotherapy. In this …

Currently, vaccine is a promising tumor prevention modality in cancer therapy. However, it is
hard to elicit robust antitumor immunity in patients already afflicted with tumor, inspiring a …

Insufficient activation of the stimulator of interferon genes (STING) signaling pathway and
profoundly immunosuppressive microenvironment largely limits the effect of cancer …

Agonists of stimulators of interferon genes (STING) are a promising class of
immunotherapeutics that trigger potent innate immunity. However, the therapeutic efficacy of …

Solid cancers are able to escape immune surveillance and are resistant to current treatment
in immunotherapy. Recent evidence indicates the critical role of the stimulator of interferon …

Nanovaccine-based immunotherapy has been considered as a major pillar to stimulate the
host immune system to recognize and eradicate tumor cells as well as establish a long-term …

Cancer vaccines targeting patient-specific neoantigens have emerged as a promising
strategy for improving responses to immune checkpoint blockade. However, neoantigenic …

Neoantigen-based cancer vaccines are promising for boosting cytotoxic T lymphocyte (CTL)
responses. However, the therapeutic effect of cancer vaccines is severely blunted by …

Agonists of the stimulator of interferon gene (STING) are considered as promising
therapeutics for cancer immunotherapy. However, drug-delivery barriers and adverse effects …